Xenon制药 XENE 深 沪
已收盘 12-19 16:00:00 美东时间
44.10
+0.870
+2.01%
华盛通- 最 高44.45
- 今 开43.26
- 成交量 103.54万股
- 最 低 43.26
- 昨 收 43.23
- 总市值 34.00亿
- 52周最高 46.60
- 市盈率 静 --
- 换手率 1.34%
- 52周最低 26.74
- 委 比 -72.60%
- 总股本 7710.58万
- 历史最高 50.99
- 量 比 1.20
- 振 幅 2.75%
- 历史最低 2.10
- 每 手 1
- 风险率 4.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $48
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $44 to $48.
12-12 01:12
期权扫描 | 获准对华出售H200芯片！英伟达一末日Call单大涨超66%；CoreWeave获看涨至150美元
获准对华出售H200芯片！英伟达一末日Call单大涨超66%；华纳兄弟探索看涨期权占逾7成；CoreWeave获看涨至150美元，较现价涨近74%>>
12-09 12:02
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">Xenon Pharmaceuticals Inc. has granted equity inducement stock options totaling 39,250 shares to five new non-officer employees. The options, priced at $44.61 per share, vest over four years with monthly vesting after the first year. Xenon, a biopharmaceutical company focused on neuroscience, is advancing treatments for epilepsy, depression, and pain.</p>
12-04 22:20
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
Vancouver-based Xenon Pharmaceuticals announced it will host an investor webinar on December 10, 2025, at 10:00-11:00 AM ET, focusing on azetukalner data from AES 2025. The webinar will cover new long-term data from the X-TOLE study on focal onset seizures, real-world data on epilepsy-related depression and titration burden, and commercialization updates for azetukalner. Registration is available via the provided link, and questions can be submit...
12-03 13:30
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $60
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $57 to $60.
11-18 23:47
Xenon to Present at Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced that it will present at two upcoming investor conferences: the Stifel 2025 Healthcare Conference on November 13, 2025, and the Jefferies Global Healthcare Conference in London on November 19, 2025. Webcast links and additional event details are available on the company's website. Xenon, a neuroscience-focused biopharmaceutical company, is advancing life-changing therapeutics for epilepsy, depres...
11-06 13:30
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $55 Price Target
Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $55 price target.
11-04 17:17
